Results 301 to 310 of about 1,398,610 (367)

Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B

Hepatology, 2022
Background and Aims: In the treatment of chronic hepatitis B (CHB) infection, stimulation of innate immunity may lead to hepatitis B virus (HBV) cure.
Cong Xu, Jieqing Fan, Danyang Liu, Aimaier Tuerdi, Juanjuan Chen, Yuning Wei, Yanfang Pan, H. Dang, Xiong Wei, A. Yousif, J. Yogaratnam, Qiong Zhou, H. Lichenstein, Tian Xu   +13 more
semanticscholar   +1 more source

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.

, 2020
10013Background: 5-year follow-up of the phase 3 KEYNOTE-006 study (NCT01866319) showed pembro improved OS vs ipilimumab (ipi) in patients (pts) with advanced melanoma.
G. Long, J. Schachter, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, A. Ribas, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, T. Petrella, O. Hamid, E. Jensen, C. Krepler, S. Diede, C. Robert   +19 more
semanticscholar   +1 more source

Anti-neuroinflammatory and Neuroprotective Effects of T-006 on Alzheimer's Disease Models by Modulating TLR4-Mediated MyD88/ NF-κB Signaling.

CNS and Neurological Disorders - Drug Targets
INTRODUCTION Neuroinflammation derived from the activation of the microglia is considered a vital pathogenic factor of Alzheimer's Disease (AD). T-006, a tetramethylpyrazine derivative, has been found to alleviate cognitive deficits via inhibiting tau ...
Haiyun Chen, Xiao Chang, Jiemei Zhou, Guiliang Zhang, Jiehong Cheng, Zaijun Zhang, Jieyu Xing, Chunyan Yan, Zheng Liu   +8 more
semanticscholar   +1 more source

A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P siRNA for the Treatment of KRAS-driven Non-small Cell Lung Cancer.

Molecular Cancer Therapeutics
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers, and KRAS mutations occur in 25-30% of NSCLC. Our approach to developing a therapeutic with the potential to target KRAS mutant NSCLC was to identify a new target involved ...
C. Cina, Bharat Majeti, Zhihong O'Brien, Li Wang, J. Clamme, Roger Adami, Kwok Yin Tsang, Jens Harborth, W. Ying, Sonya Zabludoff   +9 more
semanticscholar   +1 more source

Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.

Journal of Clinical Oncology, 2019
2505 Background: CPI-006 inhibits CD73, a nucelotidase that converts AMP to adenosine and functions as a lymphocyte adhesion molecule. CPI-006 is a humanized IgG1 FcγR binding-deficient antibody that binds to CD73+ T and B lymphocytes leading to ...
J. Luke, J. Powderly, J. Merchan, M. Barve, A. Hotson, M. Mobasher, L. Kwei, G. Luciano, J. Buggy, E. Piccione, Richard A. Miller   +10 more
semanticscholar   +1 more source

A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity.

Journal of Clinical Oncology, 2019
2641 Background: ECI-006 is a combination of TriMix (mRNAs encoding for dendritic cell [DC] activating molecules [CD40L, CD70 and caTLR4]), and mRNAs encoding for melanoma-specific tumor-associated antigens (TAAs): tyrosinase, gp100, MAGE-A3, MAGE-C2 ...
Ana Maria Arance Fernandez, J. Baurain, C. Vulsteke, A. Rutten, A. Soria, J. Carrasco, B. Neyns, B. Keersmaecker, T. Assche, B. Lindmark   +9 more
semanticscholar   +1 more source

Novel neuroprotective tetramethylpyrazine analog T-006 promotes neurogenesis and neurological restoration in a rat model of stroke

NeuroReport, 2019
Neuronal death is among the deleterious pathological changes that occur after cerebral ischemia and can lead to transient or permanent neurological deficits.
Liangmiao Wu, Jie Cao, Ning Li, Haiyun Chen, Wei Liu, Gao-xiao Zhang, Yu Liu, Yuqiang Wang, Yewei Sun, Zaijun Zhang   +9 more
semanticscholar   +1 more source

Abstract 5917: A novel lipid nanoparticle (NBF-006) encapsulating glutathione S-transferase P (GSTP) siRNA for the treatment of KRAS-driven non-small cell lung cancer

Experimental and Molecular Therapeutics, 2018
Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers and KRAS mutation occurs in 25-30% of NSCLC. Therapeutics directly targeting KRAS mutant proteins are currently not available.
Zhihong O’Brien, Li Wang, B. K. Majeti, J. Clamme, Robiel Baclig, James Chu, S. Fong, J. Harborth, J. Ibarra, Haiqing Yin, Jing Yu, Clayton Zhang, R. Adami, S. Zabludoff, W. Ying   +14 more
semanticscholar   +1 more source

The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer’s Disease

Journal of Molecular Neuroscience, 2021
Guiliang Zhang, Jiahui Wu, Chunhui Huang, Jiehong Cheng, Zhiyang Su, Zeyu Zhu, Xifei Yang, Baojian Guo, Liangmiao Wu, Zaijun Zhang, Gao-xiao Zhang, Haiyun Chen, Yewei Sun, Yuqiang Wang   +13 more
semanticscholar   +1 more source

O-006

Epidemiology, 2012
Yueh-Hsiu Mathilda Chiu, Robert O. Wright, Alexandros Gryparis, Brent Coull, Rosalind J. Wright   +4 more
openaire   +1 more source